Based on its physiological importance combined with a highly complex, multifaceted regulation, NHE3 including its molecular regulators hold enormous potential as therapeutic targets to treat diarrheal diseases as well as constipation, particularly in CF patients. This evidence concerns the gene SLC9A3 and cystic fibrosis.